The global acquired orphan blood disease market is estimated to expand at a CAGR of 10.4% and value of US$ 21.5 Bn by 2032, up from US$ 8 Bn in 2022. North America is expected to remain the leading regional market through the forecast period of 2022 to 2032.
“Increasing Per Capita Income in Developing Nations”
At present, the per capita income of people living in developing countries is increasing at a noticeable speed that further bolsters their capacity to spend more on advanced healthcare solutions. The factor is likely to increase sales avenues in the global acquired orphan blood disease market.
The emergence of novel therapies is expected to open up new avenues for industry players. Moreover, in many emerging markets, for instance, India is also anticipated to create various new growth opportunities in the market while contributing to the demand avenues.
Request for sample copy of report: https://www.persistencemarketresearch.com/samples/4464
“Increasing Prevalence of Blood-Related Diseases in North America”
North America is anticipated to hold a dominating position in the market owing to the rising count of blood-related diseases in the region. In addition, increased R&D investment in novel drugs and growing access to healthcare insurance facilities, especially in the U.S. are estimated to influence growth opportunities in the regional market.
After North America, Europe is also expected to grow at a noticeable speed in the years ahead due to the presence of well-structured and advanced healthcare solutions. East Asia and South Asia & Pacific regions are projected to grow at a rapid pace owing to increasing government initiatives for effective healthcare facilities and rising healthcare infrastructure. The presence of a larger patient population in the regions is expected to drive demand opportunities in the regional markets.
Get customized report as per requirement: https://www.persistencemarketresearch.com/request-customization/4464
Acquired Orphan Blood Disease Industry Research by Category
- Recombinant Factor
- Immunoglobulin Infusion Therapy
- Activated Prothrombin Complex Concentrate
- Thrombopoietin Receptor Agonists
By Disease Indication:
- Acquired Agranulocytosis
- Acquired Hemophilia
- Acquired Von Willebrand Syndrome
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Myelodysplastic Syndrome
Get full access of report: https://www.persistencemarketresearch.com/checkout/4464
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
Key Market Players
Key companies operating in this market are Alexion Pharmaceuticals, Inc., Amgen, Inc., Celgene Corporation, Eli Lilly and Company, Sanofi S.A., GlaxoSmithKline plc, and Cyclacel Pharmaceuticals, Inc. Some of the other companies operating in this market are Onconova Therapeutics, Inc., Incyte Corporation, and CTI BioPharma Corp.
Other Trending Reports:
- Tissue Culture Reagents Market
- Ureteral Catheters Market
- Drug Screening Market
- Radiation Dose Management Market
- Spinal Muscular Atrophy (SMA) Treatment Market
- In Vitro Protein Expression Market
- Fluid Warmer Devices Market
- Surgical Fluid Disposal Market
- Ventilator Test Systems Market
- Cancer Supportive Care Products Market
About Persistence Market Research
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
USA – Canada Toll-Free: 800-961-0353